ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Cancer Treat Rev · 2026-01-12

Meta-analysis of 8 RCTs (3,978 patients, ER+/HER2- advanced breast cancer): novel oral SERDs did not significantly improve PFS overall vs standard treatment (HR 0.80, p=0.09); benefit in the ESR1-mutated subgroup (HR 0.57). Grade ≥3 TRAEs higher (RR 1.64).

Meta-analysisn = 3,978
Kirmani et al. Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2- advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials
Oncology · Cancer Treat Rev · 2025-12-03

Systematic review and network meta-analysis of 20 RCTs (4,716 patients) with HR+ advanced breast cancer after CDK4/6i: in ESR1-mutated tumours, adding CDK4/6i or mTORi to oral SERDs improved PFS vs oral SERD/SERM/PROTAC alone (HR 0.44 and 0.45).

Meta-analysisn = 4,716
Escudero et al. Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.